Affordable Access

deepdyve-link
Publisher Website

Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study

Authors
  • Koroki, Yosuke1
  • Imanaka, Keiichiro1
  • Yasuda, Yukiko1
  • Harada, Sayuri1
  • Fujino, Akiko1
  • 1 Janssen Pharmaceutical K.K., Japan , (Japan)
Type
Published Article
Journal
Japanese Journal of Clinical Oncology
Publisher
Oxford University Press
Publication Date
May 29, 2021
Volume
51
Issue
9
Pages
1452–1461
Identifiers
DOI: 10.1093/jjco/hyab077
PMID: 34050660
PMCID: PMC8405844
Source
PubMed Central
Keywords
Disciplines
  • AcademicSubjects/MED00300
License
Unknown

Abstract

This large-scale, real-world, post-marketing surveillance study in Japan confirmed the safety and efficacy of abiraterone acetate plus prednisolone in castration-resistant prostate cancer patients with or without previous chemotherapy.

Report this publication

Statistics

Seen <100 times